Who qualifies for semaglutide treatment?
Most people searching this question already know semaglutide exists. What they do not know is whether their own numbers and health history put them on the right side of the clinical threshold. The answer depends on three things: body mass index, the presence of certain health conditions, and a review of your medical history by a licensed physician.
FDA-approved labelling sets out the criteria, and a clinician applies them to your individual situation. No online calculator can do that final step. This guide explains each criterion plainly so you arrive at your semaglutide eligibility assessment knowing what will be reviewed and why.
The BMI thresholds and what they mean
BMI is the starting point. The approved labelling for weight-management semaglutide identifies two qualifying bands.
- BMI of 30 or above, qualifies on BMI alone, with no additional condition required.
- BMI of 27 or above, qualifies only when at least one weight-related health condition is also present.
BMI is a blunt instrument. It does not distinguish muscle from fat, and it does not account for how weight is distributed. A clinician reviewing your case will look at waist circumference, metabolic markers, and overall clinical picture alongside the number. The BMI threshold is a gateway, not the whole story. You can read more about how the numbers are applied on the BMI requirements page.
Weight-related health conditions that affect candidacy
If your BMI sits between 27 and 29.9, at least one qualifying comorbidity must be present. These are conditions that are caused or worsened by excess weight and that improve with weight reduction.
- Type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- Elevated cholesterol or triglycerides (dyslipidaemia)
- Obstructive sleep apnoea
- Cardiovascular disease
This list reflects the conditions studied in the major clinical trials and referenced in approved labelling. A clinician here reviews your records to confirm the diagnosis is documented, not simply self-reported. If you have been told you have any of these conditions, bring the relevant records or a recent lab panel to your appointment. The qualifying health conditions page covers each one in more detail.
Patients managing type 2 diabetes alongside weight concerns may also want to read the guide on GLP-1 and type 2 diabetes, since the clinical picture and monitoring approach differ slightly.
Medical history the physician will review
BMI and comorbidities open the door. Medical history determines whether it is safe to walk through it. Several conditions and circumstances rule out semaglutide regardless of weight.
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or any GLP-1 receptor agonist
- Active pancreatitis or a documented history of recurrent pancreatitis
- Pregnancy or planned pregnancy during treatment
These are not arbitrary cautions. The thyroid and pancreas contraindications appear in the FDA-approved labelling because the mechanism of GLP-1 receptor agonism carries a theoretical risk in those populations. A clinician will ask about family history specifically, not just your own diagnoses. The full list of situations that rule out treatment is covered on the who should not take GLP-1 page.
Medication history also matters. If you are currently taking insulin or a sulphonylurea, the interaction with semaglutide requires careful management. A review of all current medications, including supplements, is part of the standard drug interactions screen.
Why a physician assessment cannot be skipped
Eligibility criteria are written as population-level rules. A physician assessment applies them to one person. Two patients with identical BMI readings can have very different clinical pictures, and the appropriate path forward differs accordingly.
The assessment at Houston Semaglutide typically covers current weight and BMI, a review of relevant lab work, a medication and allergy history, a discussion of previous weight-loss attempts, and a conversation about what the programme involves day to day. It is not a formality. It is the step that determines whether semaglutide is appropriate, which formulation fits your situation, and what monitoring will look like during treatment.
The physician-supervised program is structured around ongoing clinical oversight, not a single prescription and a goodbye.
Honest limits every candidate should know
Semaglutide is not appropriate for everyone who wants to lose weight. Some people are ruled out on medical grounds. Others may qualify on paper but find the practical demands of the programme do not fit their current circumstances.
A few things worth knowing before you start the process:
- The medication requires a weekly injection under the skin. There is an oral tablet form, but it is less commonly prescribed for weight management.
- Nausea is common in the first weeks of treatment, particularly during dose increases. Most people find it manageable, but it is real. The guide on nausea and digestion explains what to expect.
- When the medication stops, appetite returns. The weight-management effect is tied to continued use. This is not a short course.
- Results vary. Clinical trials reported averages around fifteen percent of body weight over roughly sixty-eight weeks for the highest studied dose, but individual outcomes differ based on adherence, diet, activity, and metabolic factors.
None of this is a reason not to explore the option. It is a reason to go in with accurate expectations rather than optimistic ones.
What semaglutide costs and what affects it
Cost is part of the eligibility conversation in a practical sense. A treatment that cannot be sustained financially will not produce lasting results.
Programme fees and medication costs are two separate figures. The programme fee covers clinical oversight, monitoring, and support. The medication cost depends on whether a brand-name or compounded formulation is prescribed, and on your insurance situation. Pricing depends on the formulation, the dose, and the pharmacy used. Figures are example ranges only and are not quotes, your actual cost is quoted at the assessment.
Commercial insurance sometimes covers weight-management semaglutide, but prior authorisation is almost always required and approval is not guaranteed. Public health insurance has historically excluded weight-loss drugs. A clinician can advise on what documentation strengthens a prior authorisation request. The insurance and coverage page outlines the process in more detail.
For a clearer picture of what the programme itself involves financially, the program cost page breaks down what is typically included.
Common eligibility questions answered directly
My BMI is 26. Can I still qualify?
Not under current approved labelling for weight management. The lower threshold is 27, and only with a documented comorbidity. If your BMI is close to 27, a clinician can measure it properly and review your full picture. Self-calculated BMI is often slightly off.
I have tried other weight-loss medications before. Does that affect eligibility?
It can. A history of poor tolerance or adverse reactions to GLP-1 receptor agonists is relevant. A history of trying and stopping other medication classes, orlistat, phentermine, bupropion-naltrexone, is useful context but does not automatically disqualify you. Bring that history to the assessment.
Do I need a referral from my primary care doctor?
Not to begin an assessment here. A clinician at Houston Semaglutide can conduct the eligibility review directly. If your primary care physician has recent labs, bringing those saves time.
How long does the assessment take?
The initial consultation is typically thirty to forty-five minutes. It covers history, measurements, and a discussion of the programme. If lab work is needed and not already available, that may add a step before a prescription is issued.
Can I switch from tirzepatide to semaglutide, or vice versa?
Switching is possible and sometimes clinically appropriate. The two molecules work on overlapping but distinct receptor pathways. A clinician reviews the reason for switching and adjusts the starting dose accordingly. The semaglutide vs tirzepatide comparison covers the clinical differences.
The next step is a clinical review
If your BMI is 27 or above, or 30 or above without a comorbidity, and you do not have a contraindicated condition, the next step is a proper clinical assessment, not another search, not another quiz.
A clinician reviews your full picture, confirms eligibility, and explains what the programme involves before anything is prescribed. Start with the do I qualify page for a structured overview, or go directly to the free eligibility assessment to begin the process.